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Abstract: Matrix metalloproteinase-3 (MMP-3) is known to mediate neuroinflammatory processes by
activating microglia, disrupting blood–central nervous system barriers and supporting neutrophil
influx into the brain. In addition, the posterior part of the eye, more specifically the retina, the
retinal pigment epithelium (RPE) and the blood–retinal barrier, is affected upon neuroinflammation,
but a role for MMP-3 during ocular inflammation remains elusive. We investigated whether MMP-3
contributes to acute inflammation in the eye using the endotoxin-induced uveitis (EIU) model.
Systemic administration of lipopolysaccharide induced an increase in MMP-3 mRNA and protein
expression level in the posterior part of the eye. MMP-3 deficiency or knockdown suppressed
retinal leukocyte adhesion and leukocyte infiltration into the vitreous cavity in mice subjected to EIU.
Moreover, retinal and RPE mRNA levels of intercellular adhesion molecule 1 (Icam1), interleukin 6
(Il6), cytokine-inducible nitrogen oxide synthase (Nos2) and tumor necrosis factor α (Tnfα), which are
key molecules involved in EIU, were clearly reduced in MMP-3 deficient mice. In addition, loss of
MMP-3 repressed the upregulation of the chemokines monocyte chemoattractant protein (MCP)-1
and (C-X-C motif) ligand 1 (CXCL1). These findings suggest a contribution of MMP-3 during EIU,
and its potential use as a therapeutic drug target in reducing ocular inflammation.
Keywords: LPS; MMP-3; inflammation; retina; blood–retinal barrier; retinal pigment epithelium;
leukostasis
1. Introduction
The eye has evolved into a specialized, tightly regulated immune privileged organ with structural
and functional mechanisms that need to protect the integrity of the neural retina and maintain
retinal homeostasis. The blood–retinal barrier (BRB) performs a crucial function to maintain this
ocular immune privilege. Both inner and outer components of the BRB, formed by, respectively,
endothelial and retinal pigment epithelial (RPE) cells, physically separate the retina from the immune
system and prevent leukocyte infiltration from the blood vessels into the retina. Next to the BRB,
eye-specific mechanisms and the specialized, unique intraocular microenvironment also contribute
to reducing systemic and local immune responses [1]. However, acute inflammatory processes
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deteriorate into severe damage of BRB structure and functionality and result in distortion of the
retinal microenvironment. Indeed, inflammation-induced pathogenic mechanisms contribute to
vision-threatening diseases such as diabetic retinopathy, retinitis pigmentosa, glaucoma, age-related
macular degeneration (AMD) and uveitis [1,2]. Therefore, investigating the mechanisms by which
the BRB/retina responds to inflammatory stimuli is an important research question, and of crucial
importance for the development of novel therapies for multiple retinal inflammatory diseases.
Acute systemic ocular inflammation can be induced in rodents using the endotoxin-induced
uveitis (EIU) model, i.e., by intraperitoneal injection of the endotoxin lipopolysaccharide (LPS),
the major component of the outer membrane of gram-negative bacteria. This model mainly mimics
acute inflammatory responses, driven by innate immune mechanisms [1], and is therefore invaluable
in unraveling the ocular inflammatory mediators. Besides its power to investigate acute vascular
inflammation at the uveal tract [3], EIU is also a compelling tool to evaluate inflammatory responses
at the posterior part of the eye. It is characterized by an increment in adhesion of leukocytes to
the retinal vasculature and infiltration of leukocytes into the retina/vitreous cavity [4,5]. Increased
oxidative stress, inflammatory cytokines (e.g., interleukin (IL)-6 and tumor necrosis factor (TNF)-α)
and chemokines (e.g., monocyte chemoattractant protein (MCP)-1 and C-X-C motif ligand (CXCL)
1/2), and adhesion molecules (e.g., soluble vascular cell adhesion molecule (sVCAM) and intracellular
adhesion molecules (ICAMs)) are key inflammatory mediators that contribute to the pathology of
rodent EIU [5–10].
Several reports describe that matrix metalloproteinases (MMPs), i.e., Zn2+-dependent
endopeptidases that cleave both matrix and non-matrix proteins, are able to degrade basal lamina
components and tight junction proteins at the blood–brain barrier (BBB), blood–cerebrospinal fluid
barrier (BCSFB) and blood–spinal cord barrier (BSCB), thereby contributing to blood–central nervous
system (CNS) barrier disruption and neuroinflammation [11–19]. Of note, it is known that the
endothelial cells of the BBB/BSCB and the choroid plexus epithelial cells (CPE) that form the BCSFB
show similarities with, respectively, the endothelial cells of the inner BRB and the RPE cells of the
outer BRB [20]. In the brain, MMP expression is known to be upregulated by cytokines but also
by the bacterial endotoxin LPS. In addition, increased MMP-3 levels have been reported during
neuroinflammatory processes [11,14,21–26]. Indeed, the MMP-3 gene (Mmp3) promoter contains
binding sites for activator protein 1 (AP-1) and nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-κB), which can both be activated by various inflammatory cytokines [27–30]. Upregulated
MMP-3 expression/activity is then suggested to result in an impairment of the blood–CNS barriers
due to its effects on degradation of tight junction proteins and/or the basal lamina, but also by
activating microglia and stimulating expression and activation of cytokines, thereby supporting
neutrophil influx [11,16,25,31–33]. Notably, MMP-3 is shown to be expressed by all cell types in the
brain as well as by blood mononuclear cells [31]. Moreover, cultured human retinal microvascular
endothelial cells and RPE cells exposed to TNF-α secrete more MMP-3 protein [34,35]. In addition,
significantly increased MMP-3 mRNA levels are detected in RPE/choroid samples of age-related
macular degeneration (AMD) patients, indicating its importance in ocular inflammatory processes [36].
The increasing knowledge of MMP-3 as a crucial mediator of the blood–CNS barrier
integrity during neuroinflammatory conditions suggests its potential contribution to systemic
inflammation-induced alterations at the retina/BRB. In the present study, we investigated the
involvement of MMP-3 in endotoxin-induced acute inflammation in the posterior part of the mouse eye.
2. Results
2.1. Endotoxemia Induces Upregulation of Matrix Metalloproteinase-3 (MMP-3) mRNA and Protein Levels in
the Posterior Part of the Eye
To evaluate whether MMP-3 is important during EIU in the posterior segment of the eye,
the MMP-3 mRNA and protein levels were determined at different time points post LPS injection.
Real time-PCR data revealed rather low levels of Mmp3 in the RPE and the retina at baseline (0 hour
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post LPS injection (hpi)) (Figure 1A). However, after induction of endotoxemia, an increment in Mmp3
mRNA levels was observed, especially in the RPE, with a peak at 16 hpi and a decline thereafter.
Indeed, Mmp3 exhibited a 2.3- (p = not significant (NS)) and a 7.4-fold (p ≤ 0.0001) increase in mRNA
expression in the retina and RPE, respectively, at 16 hpi following LPS treatment. Consistent with
these findings, pro MMP-3 (55 kDa) protein levels were slightly augmented in the retina (Figure 1B),
but significantly elevated in the RPE at 8 and 24 hpi by 5.2- and 7.8-fold, respectively (Figure 1C).
Mature MMP-3 levels showed a trend towards an increased expression in both the retina and RPE
after LPS injection (Figure 1B,C). Interestingly, pro MMP-3 significantly increased in the vitreous cavity
at 8 and 24 hpi by 4.4- and 26-fold respectively (Figure 1D), suggesting a translocation of MMP-3 to
the vitreous after induction of endotoxemia. To further localize MMP-3 in the posterior eye segment,
immunohistochemistry was performed. MMP-3 protein expression at baseline was observed in the
endfeet and radial fibers of the Müller glia (Figure 1E). In the retinas of mice with EIU, the MMP-3
immunopositive signal was most dramatically enhanced in the outer retina, more specifically in the
radial fibers of the Müller glia, and in the RPE/choroid complex. Together, these data point to a boost
of MMP-3 expression after endotoxemia in the posterior segment of the eye, predominantly in the RPE,
and indicate a potential role of MMP-3 in LPS-induced inflammatory processes.
2.2. MMP-3 Deficient Mice Do Not Show an Aberrant Retinal Morphology or Visual Acuity
Absence of MMP-3 in MMP-3 deficient (MMP-3−/−) retina and RPE samples was confirmed
via Western blotting (Figure 2A). Next, to investigate whether MMP-3 deficiency affects basal
retinal development and morphology, spectral domain optical coherence tomography (SD-OCT)
was performed on wild-type (WT) and MMP-3−/− mouse eyes. OCT scans demonstrated no obvious
morphological differences in the retina of adult MMP-3−/− compared to WT animals (Figure 2B).
In addition, a more detailed morphometric analysis revealed no discrepancies in the thickness of
the ganglion cell complex (GCC) and the total retinal thickness, indicating that MMP-3 deficiency
does not affect retinal architecture (Figure 2C). These findings were confirmed via hematoxylin and
eosin (H&E) staining on retinal sections (Figure 2D). Indeed, morphometric analysis on H&E stained
sections showed no difference in the thickness of the retinal layers (mean thickness from NFL till
ONL: 134.1 ± 4.7 µm in MMP-3−/− mice vs. 147.6 ± 6.4 µm in WT mice, n = 3). Furthermore, retinal
functionality was evaluated via the optokinetic tracking response. Visual acuity, measured as the
highest spatial frequency (cycles/degree) eliciting an optokinetic response, showed no significant
difference between the genotypes (Figure 2E). To conclude, assessment of the retinal morphology and
the optokinetic tracking response revealed that vision and normal eye function are preserved in adult
MMP-3−/− mice.
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Figure 1. Matrix metalloproteinase-3 (MMP-3) mRNA and protein spatiotemporal expression pattern 
in the retina, retinal pigment epithelium (RPE) and vitreous of mice subjected to endotoxin-induced 
uveitis (EIU). (A) Real time-PCR analysis on retina and RPE samples from wild-type (WT) mice 
subjected to EIU revealed an apparent upregulation of Mmp3 levels in the RPE, reaching a peak 
around 16 hpi (hour post LPS injection), and returning to baseline levels at 24 hpi. Retinal samples 
demonstrated a similar upregulation in Mmp3 mRNA levels, although to a much lesser extent. 
RT-PCR data were normalized against the reference genes and were expressed as a percentage 
relative to 0 hpi; (B,C) Western blot data confirmed the PCR findings and showed a slight increase in 
pro- and mature MMP-3 levels in the retina, but a more pronounced upregulation of, in particular, 
pro MMP-3 protein in the RPE; (D) Western blot data revealed a significant increase of pro MMP-3 
levels after 8 and 24 hpi in the vitreous cavity. Lava purple staining served as a loading control;  
(E) Representative images show localization of MMP-3 immunoreactivity (green) in the Müller glia 
in the retina of healthy WT mice. The blue staining represents DAPI nuclear counterstain. EIU 
increased expression of MMP-3 in these glial fibers, but also in the RPE. Scale bar: 100 µm. Western 
blot data were normalized against Lava purple total protein stain and expressed as a percentage 
relative to 0 hpi. All data are shown as mean ± SEM, n ≥ 5, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001,  
**** p ≤ 0.0001. NFL, nerve fiber layer; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner 
nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; PL, photoreceptor layer; RPE, 
retinal pigment epithelium. 
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Figure 2. Retinal morphology and visual acuity of healthy WT and MMP-3−/− mice. (A) Absence of 
pro- and mature MMP-3 in the retina and RPE of MMP-3−/− mice was confirmed via Western blotting. 
Lava purple staining served as a loading control; (B) Representative spectral domain optical 
coherence tomography (SD-OCT) pictures showed no difference in general morphology of the retina 
in WT and MMP-3−/− mice. Scale bar: 100 µm; (C) Analysis of SD-OCT images revealed a similar 
thickness of the ganglion cell complex (GCC), which includes the nerve fiber layer (NFL), ganglion 
cell layer (GCL) and inner plexiform layer (IPL), and of the total retina in both genotypes;  
(D) Representative images of hematoxylin and eosin (H&E) stained retinal sections demonstrated no 
difference in the thickness of the retinal layers in WT and MMP-3−/− eyes. Scale bar: 50 µm; (E) Visual 
acuity, assessed in a virtual optomotor device, was found to be similar in WT and MMP-3−/− mice. 
Data are shown as mean ± SEM, n ≥ 8. NFL, nerve fiber layer; IPL, inner plexiform layer; INL, inner 
nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; PL, photoreceptor layer; RPE, 
retinal pigment epithelium. 
2.3. MMP-3 Deficiency and Knockdown Attenuates the Hypothermic Response after Endotoxemia 
To investigate the role of MMP-3 in acute inflammation in the retina and RPE, WT and 
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inflammation, which is known to induce a hypothermic response in mice, also at sub-lethal  
doses [37]. A profound drop in body temperature is indeed visible in both WT and MMP-3−/− mice at 
24 hpi, however, body temperature is significantly higher in MMP-3−/− as compared to WT animals 
(31.8 ± 0.7 °C in MMP-3−/− vs. 27.9 ± 1.1 °C in WT mice, p ≤ 0.01) (Figure 3), suggesting that MMP-3−/− 
mice are less sensitive to LPS-induced hypothermia. This protective effect of MMP-3 deficiency was 
confirmed after administration of N-Isobutyl-N-(4-methoxyphenylsulfonyl)-glycyl hydroxamic acid 
(NNGH), a commonly used semi-selective MMP-3 inhibitor [32,38–40], in WT animals. Based on the 
observed MMP-3 expression profile, NNGH (1.6 µg/µL) was injected intraperitoneally 15 min 
before, and at 6 and 14 hpi. As compared to vehicle (5% DMSO), NNGH-injected mice demonstrated 
an attenuated hypothermic response, which was similar, or even more pronounced, as compared to 
the findings in MMP-3−/− mice (33.5 ± 1.3 °C in NNGH-treated vs. 26.9 ± 1.1 °C in vehicle-treated WT 
mice, p ≤ 0.001) (Figure 3). As such, MMP-3 deficiency/reduction clearly attenuates LPS-induced 
hypothermia, supporting a devastating role of MMP-3 in endotoxemia and its contributing 
inflammatory processes in the CNS. However, when MMP-3−/− mice were treated with NNGH, body 
temperature remained higher as compared to vehicle-treated MMP-3−/− animals at 24 hpi (34.8 ± 0.7 
°C in MMP-3−/− NNGH-treated mice vs. 30.1 ± 1.2 °C in MMP-3−/− vehicle-treated mice, p ≤ 0.05) 
(Figure 3). Inhibition with NNGH thus shows an additive effect in MMP-3−/− mice, indicating that 
also other MMPs beside MMP-3 attenuate the hypothermic response induced by systemic LPS 
administration. 
Figure 2. Retinal morphology and visual acuity of healthy WT and MMP-3−/− mice. (A) Absence of
pro- and mature MMP-3 in the retina and RPE of MMP-3−/− mice was confirmed via Western blotting.
Lava purple staining served as a loading control; (B) Representative spectral domain optical coherence
tomography (SD-OCT) pictures showed no difference in general morphology of the retina in WT and
MMP-3−/− mice. Scale bar: 100 µm; (C) Analysis of SD-OCT images revealed a similar thickness of
the ganglion cell complex (GCC), which includes the nerve fiber layer (NFL), ganglion cell layer (GCL)
and inner plexiform layer (IPL), and of the total retina in both genotypes; (D) Representative images of
hematoxylin and eosin (H&E) stained retinal sections demonstrated no difference in the thickness of
the retinal layers in WT and MMP-3−/− eyes. Scale bar: 50 µm; (E) Visual acuity, assessed in a virtual
optomotor device, was found to be similar in WT and MMP-3−/−mice. Data are shown as mean± SEM,
n≥ 8. NFL, nerve fiber layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform
layer; ONL, outer nuclear layer; PL, photoreceptor layer; RPE, retinal pigment epithelium.
2.3. MMP-3 Deficiency and Knockdown Attenuates the Hypothermic Response after Endotoxemia
To investigate the role of MMP-3 in acute inflammation in the retina and RPE, WT and
MMP-3−/− animals were subjected to an experimental model of bacterial endotoxin-induced systemic
inflammation, which is known to induce a hypothermic response in mice, also at sub-lethal doses [37].
A profound drop in body temperature is indeed visible in both WT and MMP-3−/− mice at 24 hpi,
however, body temperature is significantly higher in MMP-3−/− as compared to T animals
(31.8 ± 0.7 ◦ in P-3−/− vs. 27.9 ± 1.1 ◦C in WT mice, p ≤ 0.01) (Figure 3), suggesting that
MMP-3−/− mice are less sensitive to LPS-induced hypothermia. This protective effect of MMP-3
deficiency was confirmed after administration of N-Isobutyl-N-(4-methoxyphenylsulfonyl)-glycyl
hydroxamic acid (NNGH), a co monly us d semi-selective MMP-3 inhibitor [32,38–40], in WT animals.
Based on the observed MMP-3 expression profile, NNGH (1.6 µg/µL) was inject d intr peritoneally
15 min before, and at 6 and 14 hpi. As compar d to vehicle (5% DMSO), NNGH-injected mice
demonstrate an attenuated hypothermic response, which was similar, r even more pronounced,
as compared to the findings in MMP-3−/− mice (33.5 ± 1.3 ◦C in NNGH-treated vs. 26.9 ± 1.1 ◦C
in vehicle-treated WT mice, p ≤ 0.001) (Figure 3). As such, MMP-3 deficiency/r ductio clearly
attenuat s LPS-induced hypothermia, supporting a devastating role of MMP-3 in endotoxemia and its
contributing inflammatory processes in th CNS. However, when MMP-3−/− mice were treated with
NNGH, body temperature remained higher as compa d to vehicle-treated MMP-3−/− animals at
24 hpi (34.8± 0.7 ◦C in MMP-3−/− NNGH-treated mice vs. 30.1± 1.2 ◦C in MMP-3−/− vehicle-treated
mice, p ≤ 0.05) (Figure 3). Inhibition with NNGH thus shows an additive effect in MMP-3−/− mice,
indicating that also other s beside MMP-3 attenuate the hypothermic response induced by
systemic LPS administration.
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ice. ata are shown as mean ± SEM, n ≥ 5, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
2.4. MMP-3 Deficiency or Knockdown Reduces Retinal Leukocyte Adhesion and Vitreous Infiltrating
Leukocytes in the ndotoxin-Induced veitis ( I ) odel
o st y et er t e ele ate -3 le els i t e osterior eye seg e t e iate ac te
i fla atio i t e I o el, reti al vasc lat re a a eri g le kocytes ere labele by car iac
erf sio it FI -co j gate o ca avali lecti . e ber of a ere t le kocytes as
co te at 0 a 24 i i t e ve les a arterioles o reti al ole o t re aratio s of bot
genoty es (Fig re 4 ). In baseline con itions, no ifference in the n ber of retinal le kocytes as
observe in the retina of T and MMP-3− − mice (Figure 4A,B). However, as expecte , a significant
10-fold increase in the number of adherent leukocytes was noticed in EIU-treated WT mice as co pared
to healthy WT (Figure 4A,B). Similarly, leukostasis was highly augmented in MMP-3−/− retinas
after LPS treatment vs. non-treated MMP-3−/− mice (7-fold increase) (Figure 4A,B), but to a much
lower extent (31%, p ≤ 0.05) than observed in WT mice after endotoxemia. These fin ings ere
confir e after blocking P-3 levels in ice via repeate a inistration of , hich
reduced the nu ber of adherent retinal leukocytes by 60 as co pared to vehicle-treated ice
(Figure 4 ,B). s such, blocking P-3 results in a reduced leukostasis response in the retinal
vasculature during endotoxe ia.
To further confir the inhibitory effect of P-3 on acute retinal infla ation, S - T as
applied as a non-invasive, in vivo imaging technique to quantify the number of infiltrating leukocytes
in the vitreous cavity (adjacent to the optic nerve head) at 24 hpi, in both WT and MMP-3−/− mice
(Figure 4C,D) [41–43]. The number of leukocytes significantly increased, respectively, by 3- and
2-fold in the vitreous of WT and MMP-3−/− eyes after induction of endotoxe ia (Figure 4 ).
Interestingly, although not significant, MMP-3 deficiency does seem to reduce the number of infiltrating
leukocytes in the vitreous by 13% during EIU. These findings were further confirmed using NNGH-
and vehicle-treated WT mice, subjected to LPS. Indeed, although not significant due to variability,
NNGH treatment decreased the number of infiltrating leukocytes in the vitreous by 33% during
EIU (Figure 4D).
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in flatmounted retinas from WT and MMP-3−/− mice at 24 hpi. However, leukocyte adhesion seems to 
be reduced in MMP-3−/− animals. Similarly, the number of adherent leukocytes seems to be lower in 
NNGH-treated vs. vehicle-treated WT mice at 24 hpi; Scale bar: 100 µm; (B) Quantification of 
adherent retinal leukocytes in the arterioles and venules showed significantly less adherent 
leukocytes in EIU-treated MMP-3−/− mice than in WT animals (n ≥ 5). In addition, leukostasis was also 
suppressed after repeated intraperitoneal injections of the MMP-3 inhibitor NNGH, compared to 
vehicle (5% DMSO)-injected eyes (n ≥ 4). * p ≤ 0.05, *** p ≤ 0.001 and **** p ≤ 0.0001; (C) OCT 
measurements at 24 hpi were assessed to evaluate the number of leukocytes infiltrating into the 
vitreous cavity in healthy and EIU MMP-3−/−, WT and NNGH- or vehicle-treated WT mice. 
Infiltrating leukocytes (as indicated on the single B-scan by arrows) were manually counted on five 
single B-scan images over a distance of 500 µm (red line), centered on the optic disc using fundus 
images: one B-scan image at the optic nerve head and four images at 50 µm intervals from the optic 
nerve head (two anterior and two posterior). Scale bar: 100 µm; (D) The number of infiltrating 
leukocytes in the vitreous significantly increased in both WT and MMP-3−/− mice at 24 hpi. 
Interestingly, MMP-3 deficiency, either via genetic or pharmacological manipulation, slightly 
reduced the number of infiltrating leukocytes as compared to (vehicle-treated) WT eyes (n ≥ 5). Data 
are shown as mean ± SEM, * p ≤ 0.05, **** p ≤ 0.0001. 
2.5. Inflammation-Associated Molecules Are Declined in the Retina and Retinal Pigment Epithelial (RPE) of 
MMP-3 Deficient Mice Subjected to EIU 
To determine whether MMP-3 deficiency may ameliorate ocular inflammatory responses 
induced by systemic LPS injection, and to further explore the mechanisms by which MMP-3 
deficiency suppresses the previously described inflammatory processes in the EIU mouse model, 
Figure 4. I pact of MP-3 deficiency on leukocyte adhesion in the retinal vessels and on the
amount of infiltrating leukocytes into the vitreous cavity during EIU. (A) EIU induces a prominent
augmentation in the number of firmly adhering leukocytes at the retinal vessel wall as demonstrated
in flatmounted retinas from WT and MMP-3−/− mice at 24 hpi. However, leukocyte adhesion seems
to be reduced in MMP-3−/− animals. Similarly, the number of adherent leukocytes seems to be lower
in NNGH-treated vs. vehicle-treated WT mice at 24 hpi; Scale bar: 100 µm; (B) Quantification of
adherent retinal leukocytes in the arterioles and venules showed significantly less adherent leukocytes
in EIU-treated MMP-3−/− mice than in WT animals (n ≥ 5). In addition, leukostasis was also
suppressed after repeated intraperitoneal injections of the MMP-3 inhibitor NNGH, compared to vehicle
(5% DMSO)-injected eyes (n ≥ 4). * p ≤ 0.05, *** p ≤ 0.001 and **** p ≤ 0.0001; (C) OCT measurements
at 24 hpi were assessed to evaluate the number of leukocytes infiltrating into the vitreous cavity in
healthy and EIU MMP-3−/−, WT and NNGH- or vehicle-treated WT mice. Infiltrating leukocytes
(as indicated on the single B-scan by arrows) were manually counted on five single B-scan images over
a distance of 500 µm (red line), centered on the optic disc using fundus images: one B-scan image at the
optic nerve head and four images at 50 µm intervals from the optic nerve head (two anterior and two
posterior). Scale bar: 100 µm; (D) The number of infiltrating leukocytes in the vitreous significantly
increased in both WT and MMP-3−/− mice at 24 hpi. Interestingly, MMP-3 deficiency, either via genetic
or pharmacological manipulation, slightly reduced the number of infiltrating leukocytes as compared
to (vehicle-treated) WT eyes (n ≥ 5). Data are shown as mean ± SEM, * p ≤ 0.05, **** p ≤ 0.0001.
2.5. Inflam ation-Associated Molecules re eclined in the etina and Retinal Pigment Epithelial (RPE) of
M P-3 Deficient Mice Subjected to EIU
To determine whet r MMP-3 defici n y may ameliorate ocular inflammatory responses induced
by systemic LPS injection, and to further explore the mechanis s by which MMP-3 deficiency
suppresses the previously described inflammatory processes in the EIU mouse odel, real time
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quantitative PCR for interleukin 6 (Il6), Il1b, tumor necrosis factor alpha (Tnfα), nuclear factor kappa
B p65 subunit (Nf-κB p65), monocyte chemoattractant protein (Mcp1/Ccl2), (C-X-C motif) ligand 1
(Cxcl1) and nitric oxide synthase (Nos2) (Figure 5A–N), and cytokine bead array (CBA) for MCP-1
and CXCL1 (Figure 5O–R) were performed on WT and MMP-3−/− retinal and RPE samples at 0
and 16 hpi. Compared to WT mice, MMP-3 deficiency did not affect the basal mRNA expression
patterns of any of the inflammation-associated genes in the retina or RPE (Figure 5A–N). Notably,
mRNA levels of these inflammatory molecules were very low to undetectable. After EIU induction,
the levels of all genes were significantly increased in WT and MMP-3−/− mice in both the retina
and the RPE (Figure 5A–N), except for Il1b in the RPE, which only showed a small increment in
both genotypes (Figure 5J). Moreover, not all inflammatory molecules were equally augmented in
WT mice with EIU, including differences between retina and RPE samples. Indeed, while Il1b seems
barely upregulated after EIU in the mouse retina and RPE, Mcp1 and Cxcl1 are the most affected genes
during EIU, especially in the retina. In addition, Il6, Nos2 and Tnfα are clearly upregulated after LPS
injection. Furthermore, this increment in Il6 and Nos2 levels was more pronounced in the RPE than in
the retina, similar as for Nf-κB p65. Interestingly, compared to WT mice with EIU, MMP-3 deficiency
(significantly) reduced the retinal and RPE mRNA levels of most of these inflammatory molecules,
except for Il1b in both tissues and Nf-κB p65 in the retina, which are expressed only at low levels in
these tissues during EIU. In addition, while protein levels of MCP-1 and CXCL1 were undetectable
in retina and RPE of both MMP-3−/− and WT eyes in baseline conditions, they were increasingly
observed in the two genotypes at 16 hpi (Figure 5O–R). Strikingly, MMP-3 deficiency clearly reduced
the level of both chemokines in retina and RPE samples (Figure 5O–R). Indeed, MCP-1 levels were
significantly reduced by 81% (p ≤ 0.01) in the retina and by 56% (p ≤ 0.05) in the RPE of MMP-3−/−
mice in comparison to WT animals. Accordingly, MMP-3 deficiency reduced CXCL1 levels by 98% in
the retina and by 47% in the RPE, yet variability in samples prevented to reach statistical significance.
Overall, our data reveal that MMP-3 deficiency clearly reduces the inflammatory response after EIU in
the retina and RPE.
2.6. Impact of MMP-3 on the Adhesion Molecule Intercellular Adhesion Molecules (ICAM)-1 after EIU in the
Retina and RPE
Next to the cytokines and chemokines described above, the adhesion molecule ICAM-1 is also a
well-known and important modulator of leukocyte recruitment and adhesion during inflammation
in the retina and RPE [2,44,45]. To investigate whether ICAM-1 levels are influenced by MMP-3 in
the EIU model and thereby contribute to the observed reduction in adherent leukocytes/infiltrating
leukocytes, changes in the gene and protein expression levels of ICAM-1 were explored in control
and LPS-treated WT and MMP-3−/− eyes. In the healthy WT and MMP-3−/− retina and RPE, Icam1
mRNA levels were barely detectable (Figure 6A,B). However, EIU induction in WT mice resulted in a
significant upregulation of Icam1 mRNA in the retina and the RPE. Importantly, MMP-3 deficiency
clearly attenuated the gene expression levels of Icam-1, since a reduction of 76% of Icam1 was observed
in both the retina (p ≤ 0.05) and RPE (p ≤ 0.0001) of MMP-3−/− mice as compared to WT mice.
To confirm the effect of MMP-3 deficiency on the reduction of Icam-1 expression, additional Western
blot experiments were performed to investigate ICAM-1 at the protein level, both in retina and RPE
samples (Figure 6C,D). In the retinas of mice with EIU, only a limited upregulation of ICAM-1 protein
expression was observed, and the attenuating effect of MMP-3 deficiency was no longer obvious.
However, in the RPE, ICAM-1 protein levels were significantly increased after EIU in both WT and
MMP-3−/− eyes. Importantly, MMP-3 deficiency clearly reduced the levels of ICAM-1 during EIU,
more specifically by 35% as compared with WT RPE samples. As such, after EIU induction, our data
suggest that MMP-3 affects ICAM-1 expression at the posterior part of the eye, especially at the RPE.
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deficiency reduces its levels in the RPE, yet not significantly; Il1b (I,J) showed only a limited 
upregulation in WT and MMP-3−/− retinal and RPE samples subjected to EIU, and no clear difference 
was revealed between WT and MMP-3−/− mice after LPS. For most of the inflammatory molecules, the 
highest increase in mRNA levels, as well as the most pronounced difference between the WT and 
MMP-3−/− condition, is observed in the RPE. RT-PCR data were normalized against the reference 
genes and were expressed as a percentage relative to 0 hpi (n ≥ 3); (O–R) Retinal and RPE samples 
from WT and MMP-3−/− mice with or without LPS injection were also analyzed for the 
pro-inflammatory chemokines MCP-1 (O,P) and CXCL1 (Q,R) at the protein level via cytometric 
bead array at 16 hpi. Levels of both MCP-1 and CXCL1 are significantly upregulated after EIU in WT 
mice and MMP-3 deficiency clearly suppressed this augmentation, especially the MCP-1 protein 
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Figure 5. MMP-3 deficiency prevents strong upregulation of infla atory-associated molecules in
the retina and RPE during EIU. (A–N) The gene expression levels of interleukin 6 (Il6), nitric oxide
synthase (Nos2), tumor necrosis factor alpha (Tnfα), nuclear factor kappa B p65 subunit (Nf-κB p65), Il1b
and monocyte chemoattractant protein (Mcp1/Ccl2), (C-X-C motif) ligand 1 (Cxcl1) were performed on
WT and MMP-3−/− retinal and RPE samples at 0 and 16 hpi. Healthy retina and RPE samples from WT
and MMP-3−/− mice showed very low to undetectable mRNA levels. Most of the inflammatory genes,
i.e., Il6 (A,B), Nos2 (C,D), Tnfα (E,F), Mcp1 (K,L) and Cxcl1 (M,N) were significantly upregulated in WT
eyes subjected to EIU (16 hpi), and to a much lesser extent, in the MMP-3−/− retina and RPE; Nf-κB
p65 (G,H) is predominantly upregulated in the RPE, and MMP-3 deficiency reduces its levels in the
RPE, yet not significantly; Il1b (I,J) showed only a limited upregulation in WT and MMP-3−/− retinal
and RPE samples subjected to EIU, and no clear difference was revealed between WT and MMP-3−/−
mice after LPS. For most of the inflammatory molecules, the highest increase in mRNA levels, as well
as the most pronounced difference between the WT and MMP-3−/− condition, is observed in the
RPE. RT-PCR data were normalized against the reference genes and were expressed as a percentage
relative to 0 hpi (n ≥ 3); (O–R) Retinal and RPE samples from WT and MMP-3−/− mice with or
without LPS injection were also analyzed for the pro-inflammatory chemokines MCP-1 (O,P) and
CXCL1 (Q,R) at the protein level via cytometric bead array at 16 hpi. Levels of both MCP-1 and CXCL1
are significantly upregulated after EIU in WT mice and MMP-3 deficiency clearly suppressed this
augmentation, especially the MCP-1 protein levels. Data are shown as mean ± SEM, n ≥ 5, * p ≤ 0.05,
** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001. Data with no indicated statistical analysis point out no
significant results.
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Figure 6. The effect of MMP-3 deficiency on ICAM-1 mRNA and protein levels in the retina and RPE 
during EIU. (A,B) Real time-PCR data revealed significantly elevated levels of Icam1 at 16 h after EIU 
induction in the posterior eye segment of WT eyes. This augmentation was significantly reduced in 
retinal and RPE samples of MMP-3−/− mice as compared to WT animals. Data were normalized 
against the reference genes and were expressed as a percentage relative to 0 hpi (n ≥ 3); (C) The 
protein level of ICAM-1 in the retina only showed a slight increase after EIU, and no clear difference 
between WT and MMP-3−/− mice after LPS; (D) However, ICAM-1 in the RPE was significantly 
increased at 16 hpi in both genotypes. Interestingly, MMP-3 deficiency reduced ICAM-1 levels after 
LPS. Lava purple staining served as a loading control. Western blot data were normalized against 
Lava purple total protein stain and expressed as a percentage relative to 0 hpi. All data are shown as 
mean ± SEM, n ≥ 5, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. Data with no indicated statistical 
analysis point out no significant results. 
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Blood–Retinal Barrier (BRB) during EIU 
To investigate whether systemically-induced ocular inflammation affects the levels of the tight 
junction protein zona occludens 1 (ZO-1) at the inner (endothelial cells) and outer (RPE cells) BRB, 
and to evaluate the influence of MMP-3 deficiency on this protein, ZO-1 expression was studied at 
the transcriptional (Figure 7A) and translational (Figure 7B,C) level at 16 hpi in WT and MMP-3−/− 
RPE and retinal samples. LPS administration reduced ZO-1 mRNA and protein levels in the retina of 
WT mice, more than in the RPE (p = NS). ZO-1 levels were decreased to a similar extent in MMP-3−/− 
retina and RPE samples. Thus, ZO-1 levels seem reduced in particular at the inner BRB during EIU 
and MMP-3 deficiency did not affect ZO-1 levels in the posterior segment of the eye during EIU. 
Figure 6. The effect of MMP-3 deficiency on ICAM-1 mRNA and protein levels in the retina and RPE
during EIU. (A,B) Real time-PCR data revealed significantly elevated levels of Icam1 at 16 h after EIU
induction in the posterior eye segment of WT eyes. This augmentation was significantly reduced in
retinal and RPE samples of MMP-3−/− mice as compared to WT animals. Data were normalized against
the reference genes and were expressed as a percentage relative to 0 hpi (n ≥ 3); (C) The protein level
of ICAM-1 in the retina only showed a slight increase after EIU, and no clear difference between WT
and MMP-3−/− mice after LPS; (D) However, ICAM-1 in the RPE was significantly increased at 16 hpi
in both genotypes. Interestingly, MMP-3 deficiency reduced ICAM-1 levels after LPS. Lava purple
staining served as a loading control. Western blot data were normalized against Lava purple total
protein stain and expressed as a percentage relative to 0 hpi. All data are shown as mean ± SEM, n ≥ 5,
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. Data with no indicated statistical analysis point out
no significant results.
2.7. MMP-3 Deficiency Does Not Influence Zona Occludens 1 (ZO-1) Levels at the Inner or Outer
Blood– etinal Barrier (B B) during EI
To investigate hether syste ically-induced ocular infla ation affects the levels of the tight
junction protein zona occludens 1 ( -1) at the inner (endothelial cells) and outer (RPE cells) BRB,
and to evaluate the influence of P-3 deficiency on this protein, -1 expression as studied at
the transcriptional (Figure 7 ) and translational (Figure 7B,C) level at 16 hpi in WT and M P-3−/−
PE and retinal sa ples. LPS ad inistration reduced -1 and protein levels in the retina of
T ice, ore than in the PE (p = S). Z -1 levels were decreased to a similar extent in M P-3−/−
retina and PE sa ples. Thus, -1 levels see reduced in particular at the inner B B during EI
and P-3 deficiency did not affect Z -1 levels in the posterior seg ent of the eye during EI .
Int. J. Mol. Sci. 2016, 17, 1825 11 of 23
Int. J. Mol. Sci. 2016, 17, 1825 11 of 23 
 
 
Figure 7. The impact of MMP-3 deficiency on ZO-1 in the retina and RPE during EIU. (A) Real 
time-PCR data showed a clear reduction, although not significant, in Zo1 mRNA levels in the retina 
of WT and MMP-3−/− mice after EIU induction, which was not observed in the RPE; (B,C) Additional 
Western blot analysis of ZO-1 in the retina and RPE confirmed these data. Lava purple staining 
served as a loading control. Western blot data were normalized against Lava purple total protein 
stain and expressed as a percentage relative to 0 hpi. (A–C) MMP-3 deficiency did not affect ZO-1 
levels during EIU at the posterior eye segment. Data are shown as mean ± SEM, n ≥ 5. 
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pathogenesis of highly prevalent ocular diseases such as diabetic retinopathy, age-related macular 
degeneration (AMD), Behçet’s disease, retinitis pigmentosa and posterior uveitis [4,49,50]. 
Therefore, a potential common therapeutic strategy in combatting these disorders will presumably 
link with the regulation of inflammatory processes [50]. 
In this study, we provide important evidence for the contribution of MMP-3 to acute retinal 
inflammation, using a mouse model of endotoxin-induced uveitis (EIU). At first, before induction of 
EIU, retinal morphology and visual acuity were investigated in MMP-3 deficient and WT mice. No 
difference in both measurements was observed between the genotypes, meaning that MMP-3 is 
seemingly dispensable for proper formation of retinal layers and normal visual functioning. 
However, we cannot rule out any proteolytic redundancy or enzymatic compensation during 
development in the MMP-3−/− mice. Indeed, the lack of clear phenotypes in MMP mutant mice has 
been attributed to, amongst others, the overlapping substrates between MMPs or the upregulation 
of other MMPs within this large family [51]. 
We confirmed the presence of MMP-3 in the healthy retina, more specifically in Müller glia end 
feet and their fibers located in the inner retina, as previously described [52]. EIU promoted MMP-3 
mRNA and protein levels to some extent in the retina, but dramatically induced its expression in the 
RPE. Notably, our data also demonstrated an increased MMP-3 protein secretion into the vitreous, 
suggesting a possible translocation of MMP-3 from the inner retina to the vitreous after LPS. 
Remarkably, especially pro MMP-3 levels were found to be upregulated in the RPE and vitreous 
after LPS treatment. MMPs, and also MMP-3, are classically activated via proteolytic cleavage of the 
Figure 7. The impact of MMP-3 deficiency on ZO-1 in the retina and RPE during EIU. (A) Real
ti e-PCR data showed a clear reduction, although not significant, in Zo1 mRNA levels in the retina of
WT and M P-3−/− ice after EIU induction, hich as not observed in the RPE; (B,C) Additional
estern blot analysis of ZO-1 in the retina and RPE confirmed these data. Lava purple staining served
as a loading control. Western blot data were normalized against Lava purple total protein stain and
expressed as a percentage relative to 0 hpi. (A–C) MMP-3 deficiency did not affect ZO-1 levels during
EIU at the posterior eye segment. Data are shown as mean ± SEM, n ≥ 5.
3. Discussion
lthough matrix metalloproteinase-3 (MMP-3 or stromelysin-1) has been described to importantly
contribute to several neuroinflammatory processes, such as leukocyte adhesion and infiltration,
micro/macroglial activation, release/activation of cytokines and free radicals in the brain and spinal
cord and at its barriers [11,16,31,46–48], we aimed to investigate the role of this protease in acute
inflammation in the eye, with a focus on the retina, the RPE and the blood–retinal barrier (BRB).
These studies are of fundamental significance to increase our understanding of ocular inflammation,
as inflammatory processes and BRB dysfunctions are strongly implicated in the pathogenesis of
highly prevalent ocular diseases such as diabetic retinopathy, age-related macular degeneration
(AMD), Behçet’s disease, retinitis pigmentosa and posterior uveitis [4,49,50]. Therefore, a potential
common therapeutic strategy in combatting these disorders will presumably link with the regulation
of inflammatory processes [50].
In this study, e provide i portant evidence for the contribution of P-3 to acute retinal
infla ation, using a mouse model of endotoxin-induced uveitis (EIU). At first, before induction
of EIU, retinal morphology and visual acuity were investigated in MMP-3 deficient and WT mice.
No difference in both measurements was observed between the genotypes, meaning that MMP-3 is
see ingly dispensable for proper formation of retinal layers and normal visual functioning. However,
we cannot rule out any proteolytic redundancy or enzymatic compensation during development in the
MMP-3−/− mice. Indeed, the lack of clear phenotypes in MMP mutant mice has been attributed to,
amongst others, the overlapping substrates between MMPs or the upregulation of other MMPs within
this large family [51].
e confir ed the presence of MMP-3 in the healthy retina, more specifically in Müller glia end feet
and their fibers located in the inner retina, as previously described [52]. EIU promoted MMP-3 mRNA
and protein levels to some extent in the retina, but dramatically induced its expression in the RPE.
Notably, our data also demonstrated an increased MMP-3 protein secretion into the vitreous, suggesting
a possible translocation of MMP-3 from the inner retina to the vitreous after LPS. Remarkably,
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especially pro MMP-3 levels were found to be upregulated in the RPE and vitreous after LPS
treatment. MMPs, and also MMP-3, are classically activated via proteolytic cleavage of the pro-peptide,
which results in opening of the cysteine-to-zinc switch. After activation, mature MMP-3 exerts its
function and will soon be captured, presumably by tissue inhibitors of metalloproteinases (TIMPs),
and possibly be proteolytically degraded and physically cleared to maintain tissue homeostasis [52,53].
Alternatively, MMP-3 can also be activated via non-proteolytic compounds such as sulfydryl-reactive
agents and reactive oxygen species (ROS), which react with the sulfydryl groups and inactivate the
cysteine without pro-peptide removal [53,54]. As such, pro MMP-3 might, after activation by ROS,
which is known to be quickly induced by LPS and shown to be involved in ocular inflammatory
disorders [55–57], exert its functions and contribute to acute inflammatory processes. Thus far,
however, there are no data that could explain the role or function of MMP-3 in the vitreous during
ocular inflammation. Nevertheless, our findings in retinal and RPE tissue correspond to the observed
increment in MMP-3 levels during the early neuroinflammatory phase after brain and spinal cord
injury [16,58].
Increased transcription (and translation) of MMP-3 during EIU can be elicited via inflammatory
cytokines, as the Mmp3 gene contains binding sites for the transcription factors AP-1 and NF-κB in its
promoter region. Indeed, many of the responses to the pro-inflammatory cytokine TNF-α require de
novo gene expression regulated by these transcription factors [27–29,59]. As such, our data suggest
that the upregulated levels of TNF-α during EIU might induce expression of (the p65 subunit of)
NF-κB, especially at the RPE, thereby mediating production of MMP-3 in this tissue. The endotoxin
LPS is known to activate the inflammatory cascade via Toll-like receptor 4 (TLR4), present on immune
cells, including neutrophils, macrophages and lymphocytes, but also on epithelial cells, including
choroid plexus epithelial (CPE) cells, whereby the stimulation of TLR4 by LPS causes the release of
pro-inflammatory cytokines, including IL-6 and TNF-α, necessary to activate potent immune responses,
such as the adhesion and activation of leukocytes [60–63]. Previous findings also indicate the presence
of TLR4 receptors on human RPE cells, which upon ligand binding lead to nuclear translocation of
NF-κB and subsequently, the activation of pro-inflammatory cytokines [64]. Interestingly, an increase
in MMP-3 levels has already been demonstrated in cultured human RPE cells after oxidative stress [65]
and in the presence of TNF-α [34,35], as well as in RPE/choroid samples of AMD patients and of
old mice compared to those of young animals [36,66]. Moreover, treatment of porcine CPE cells with
TNF-α or the Streptococcus suis bacterium also induced a clear upregulation in Mmp3 gene expression
levels [2,67]. Finally, it has also been described that intracerebral injection of LPS stimulates the
expression of MMP-3 in brain tissue [21] and intracerebroventricular injection of Aβ1-42 oligomers,
a validated Alzheimer’s disease mouse model characterized by a strong inflammatory response at
the CPE and associated disruption of the BCSFB, revealed a marked upregulation of MMP-3 mRNA
and protein expression in CPE cells [14]. Overall, our data show a prominent upregulation of MMP-3
during acute neuroinflammatory responses at the posterior part of the eye, more specifically at the
RPE, suggesting an important role for this protease in modulating ocular inflammation.
Consistent with previous mouse EIU studies, the number of leukocytes that firmly adhered to
the retinal vasculature in WT or vehicle-treated eyes was significantly increased during EIU [4,5].
Importantly, our study established, using genetic and pharmacological approaches, that MMP-3 is
involved in leukocyte adhesion during acute inflammation in the eye. As such, our data disclosed
a clearly reduced leukostasis in MMP-3 deficient mice compared to WT animals. Moreover, a trend
towards a diminished number of infiltrating vitreous leukocytes at the optic nerve head, a known
site for early infiltration, was observed in MMP-3−/− mice, as compared to WT eyes, after induction
of endotoxemia. Administration of the pharmacological MMP-3 inhibitor NNGH even resulted
in a more pronounced decrease in leukocyte adhesion. In addition, the attenuated hypothermic
response was also more explicit after pharmacological than genetic inactivation of MMP-3 after
systemic LPS injection. This small discrepancy in body temperature and leukocyte adhesion between
MMP-3−/− and NNGH inhibitor-treated mice might be due to the implication of other MMPs, beside
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MMP-3, in LPS-associated inflammatory processes. Indeed, MMPs are well known to modulate
LPS-induced inflammatory responses, such as leukocyte rolling and adhesion, neutrophil influx and
the activation of cytokines, and might as such contribute to the hypothermic response. Although the
precise mechanisms underlying hypothermia are not fully understood, many inflammatory mediators
seem to contribute to this complex process [68–70]. Importantly, several expression studies have
observed upregulation of multiple MMPs, including MMP-3, after an LPS challenge in different
cell types and organs, and inhibition of MMPs via broad-spectrum MMP inhibitors clearly showed
protection against endotoxic shock [13,71,72]. Furthermore, MMP-7, -8, -12 and -13 deficient mice
were also previously reported to show protection against death and hypothermia in the systemic LPS
mouse model [13,73–75]. Although NNGH is a potent inhibitor of MMP-3, it also blocks MMP-1,
MMP-2, MMP-7, MMP-8, MMP-9, MMP-10, MMP-12, MMP-13, MMP-14, and MMP-20 activity.
Treatment of MMP-3−/− mice with NNGH resulted in a reduced hypothermic response as compared
to vehicle-injected MMP-3−/− animals. Together, these findings suggest that absent/decreased MMP-3
levels during EIU exert protective and anti-inflammatory effects. Moreover, these results also indicate
that one or several of the above mentioned MMPs may provide an additive effect to MMP-3 on
the hypothermic response after endotoxin-induced acute inflammation, and thus probably also to
leukocyte adhesion/infiltration in the eye.
Several reports demonstrated an increase of IL-6 in the retina and RPE after systemic LPS injection,
where it is assumed to play an essential role in the development of EIU through activation of microglia
and astrocytes [7,76–80]. While Il6 mRNA levels was barely detected in the healthy retina and RPE
in this study, Il6 levels were strongly upregulated in the retina and RPE of EIU mice. Importantly,
MMP-3 deficiency significantly suppressed this increase in Il6 gene expression during EIU. During the
initial stages of inflammation, both the endothelium and epithelium in the CNS are stimulated by
locally produced cytokines, such as IL-6, which in turn activate/increase chemokines and adhesion
molecules [2,81]. Indeed, as confirmed in our study, chemokines, such as MCP-1 and CXCL1, but also
the adhesion molecule ICAM-1, are upregulated during EIU, thereby exerting important roles in
leukocyte recruitment and adhesion during ocular inflammation [45,80,82]. Importantly, our results
clearly disclosed a reduction of MCP-1 and CXCL1 mRNA and protein levels in both retinal and RPE
samples of MMP-3 deficient mice during EIU. Our data also demonstrated low Icam1 mRNA expression
in the healthy retina and RPE, and an elevation of Icam1 levels in the inflamed retina and RPE/choroid
complex. Western blot data revealed a similar increase in ICAM-1 protein levels in the RPE during EIU,
yet this upregulation was reduced in retinal samples, indicating that ICAM-1 especially plays a pivotal
role in regulating leukocyte adhesion at the RPE during retinal injury. These findings further support
the importance of the RPE as gateway for monocyte trafficking to the retina, similar as observed for
the epithelial barriers in the brain. As such, it was recently reported that monocytes would accumulate
first in the RPE before entering the retina [83]. Previous studies reported that shortly after systemic
LPS injection, ICAM-1, as well as its interaction partners, including leukocyte counter receptors
lymphocyte function-associated antigen 1 (LFA-1) and macrophage antigen 1 (Mac-1), are upregulated
in blood vessels of the retina and RPE/choroid complex, thereby enhancing leukocyte recruitment
and adhesion [5,45,50]. Interestingly, our data indicated that MMP-3 highly influences ICAM-1 levels
at the RPE/choroid complex, but to a lesser extent in the retina. During CNS inflammation, NOS2
(or iNOS) is a well-established source of NO, which is an important second messenger that regulates
many physiological and pathological events, including inflammatory processes. NO seems to be
pro-inflammatory in EIU because increased NOS2 levels are associated with inflammatory conditions
and inhibition of NOS2 has been shown to limit the pathogenesis of EIU [10,84]. Moreover, endotoxin
and cytokine stimulation in the EIU model was reported to induce expression of NOS2 in Müller glia
and RPE cells [84]. Interestingly in our study, MMP-3 deficiency resulted in clearly attenuated levels
of Nos2 in the retina, but especially in the RPE, again indicating an involvement of MMP-3 in the
inflammatory response in the EIU model.
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Overall, we hypothesize the existence of a feedback loop during EIU, in which activation
of TLR4 by LPS stimulates expression/activation of pro-inflammatory cytokines, amongst others
TNF-α, which in turn activates transcription factors such as NF-κB, in this case most prominently
at the RPE. Translocation of NF-κB to the nucleus is known to activate transcription of several
genes, including Mmp3, Icam1, Il6, Mcp1 and Nos2 [29,50,59,79,80]. Intriguingly, these molecules
are prominently present in the RPE/choroid tissue after systemic LPS administration. Alternatively,
also activation of the MAP kinase P38 or ERK pathway after induction of endotoxemia can possibly
trigger cytokine-induced MMP-3 transcription/translation [71,85–88]. When then MMP-3 becomes
activated, for instance by ROS, it might in turn trigger the release of TNF-α and/or activation
of pro TNF-α [89,90], thereby again contributing to the inflammatory responses and cascades.
In addition, by cleaving the protease-activated receptor-1 into an active ligand, mature MMP-3 can
contribute to microglia activation, and thus stimulate expression of cytokines and other inflammatory
molecules [31,83]. Finally, we cannot exclude the contribution of other pathways, which are known
to be affected by MMP-3, in LPS-induced inflammation in the eye. Overall, based on the above,
it is clear that when MMP-3 production/activation is prevented, this will cause a reduction in the
level of inflammation-associated molecules. Remarkably, papers describing the effect of MMP-3 on
inflammatory molecules and processes in the CNS are rather poor. It has been reported that inhibition
of MMP-3 significantly suppresses gene expression levels of Nos2, Il6, Il1b and Il1Ra in cultured
microglial cells treated with LPS [32]. We also observed a strongly diminished expression of NOS2 and
Il6 in MMP-3−/− mice as compared to WT mice, yet no effect on Il1b was found, probably due to its
very low expression levels in EIU WT mice. In addition, it is known that during acute inflammation,
MMP-3 facilitates neutrophil infiltration by disrupting the BBB and BSCB, probably via degradation
of basal lamina components and tight junction proteins including ZO-1 [11,16,33]. Previous reports
suggest that ZO-1 might play a major role in maintaining the BRB [91,92]. However, until now, studies
on the role of ZO-1 at the inner and outer BRB in mice after LPS challenge are lacking, as well as the
influence of MMP-3 on ZO-1 levels during ocular inflammation. We observed a decrease in ZO-1 levels
at 24 h post systemic LPS administration in both genotypes in the retina, but to a lesser extent in the
RPE, indicating that ZO-1 expression at the RPE is probably not affected by systemic LPS exposure.
These data are line with previous findings in rats that showed a significant decrease in retinal levels of
ZO-1, leading to an increase of inner BRB permeability, after systemic LPS administration [93], while
incubation of cultured rat RPE cells with LPS in vitro had no effect on RPE tight junctions [94]. Of note,
MMP-3 deficiency did not affect ZO-1 levels at the retina or RPE during EIU, suggesting that MMP-3
is not involved in disruption of ZO-1 at the BRB. However, future experiments are needed to further
clarify a role for MMP-3 in degradation of tight junction proteins and basal lamina components at the
inner and outer BRB during ocular inflammation.
In summary, our data provide the first evidence of MMP-3 as a strong modulator of acute ocular
inflammation in the posterior part of the eye. Specifically, MMP-3 levels are strongly upregulated
in the inflamed eye, predominantly in the RPE, during endotoxemia. Moreover, at the cellular level,
MMP-3 deficiency reduces leukocyte recruitment to the retina and vitreous cavity, and, at the molecular
level, MMP-3 clearly suppresses the upregulation of inflammation-related molecules. Thus, although
additional studies are essential to gain more insight in the exact MMP-3 working mechanisms during
ocular inflammation, these findings further support the hypothesis that MMP-3 is importantly involved
in neuroinflammatory processes, and might therefore serve as a potential therapeutic target for the
development of ocular anti-inflammatory strategies.
4. Materials and Methods
4.1. Animals
All experiments were performed using 8–12 week old C57Bl/6J wild-type (WT) and MMP-3
deficient (MMP-3−/−) mice (Mudgett, Merck Research Labs, Rahway, NJ, USA). All animals were
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housed under standard laboratory conditions according to a normal day/night rhythm with ad libitum
access to food and water. Genotyping was performed on tail DNA using the following primers
for WT DNA: 5′-aacatggagactttgtccctt-3′ as forward and 5′-cagtgacatcctctgtcc-3′ as reverse primer,
and for MMP-3−/− DNA: 5′-atactttctcggcaggag-3′ as forward and 5′-tgaatgaactgcaggacgag -3′ as
reverse primer. All animal experiments were approved by the Institutional Ethical Committee of KU
Leuven and are in strict accordance with the European Communities Council Directive of 22 September
2010 (2010/63/EU). Of note, a recently published study indicated a phenotypic interference of an
inactivating passenger mutation in the Casp11 gene within this MMP-3−/− mouse line [95]. Whether
this additional mutation affects the currently reported findings remains to be investigated. However, to
confirm our data obtained in MMP-3−/− animals, we also used a pharmacological inhibitor of MMP-3
in WT mice. Thereto, 100 µL of the MMP-3 inhibitor N-Isobutyl-N-(4-methoxyphenylsulfonyl)-glycyl
hydroxamic acid (NNGH) was administered via intraperitoneal (ip) injection at a concentration of 1.6
µg/µL (in 5% DMSO, 95% PBS), 15 min before and at 6 and 14 h after LPS treatment (hours post LPS
injection, hpi).
4.2. Endotoxemia Model
Both female and male mice received a single ip injection of lipopolysaccharides (LPS) from
Salmonella enterica serotype abortus equi (Sigma-Aldrich, St. Louis, MO, USA), diluted in Dulbecco’s
phosphate buffered saline (dPBS) at a dose of 12.5 mg/kg body weight. This dose was selected
after titration experiments and results in 80% mortality (LD80) in WT mice. Rectal temperature was
measured three times a day after LPS challenge. Mice that did not respond to LPS were omitted from
the experiments.
4.3. Quantitative Real-Time PCR
Animals were sacrificed at 0 (no LPS injection), 8, 16 and 24 hpi for WT mice and after 0 and 16 hpi
for MMP-3−/− mice (n ≥ 3), and total RNA was extracted from both retina and RPE/choroid/sclera
(further on indicated as RPE) using Tri-reagent (Sigma-Aldrich) and purified by NucleoSpin RNA
clean-up Isolation Kit (MACHEREY-NAGEL, Düren, Germany). RNA was reverse transcribed to
cDNA using Superscript III reverse transcriptase (Invitrogen, Ghent, Belgium) with poly-dT primers.
Real-time quantitative PCR for Mmp3 at 0, 8, 16 and 24 hpi and for zona occludens 1 (Zo1), intercellular
adhesion molecule 1 (Icam1), nitric oxide synthase 2 (Nos2 or iNos), interleukin 6 (Il6), Il1b, tumor
necrosis factor (Tnfα), nuclear factor kappa B p65 subunit (Nf-κB p65), monocyte chemoattractant
protein (Mcp1/Ccl2), and (C-X-C motif) ligand 1 (Cxcl1) at 0 and 16 hpi was performed using Taqman
assays (Thermo Scientific, Ghent, Belgium) and a StepOne Plus apparatus (Applied Biosystems,
Thermo Scientific). Thermal cycle parameters were 10 min at 95 ◦C, followed by 40 cycles of 10 s at 95 ◦C
and 60 s at 60 ◦C. All samples were run in duplicate. Using geNorm software (qBase, available online:
https://genorm.cmgg.be/), Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation
protein zeta (Ywhaz), 18S Ribosomal RNA (Rn18s1) and β-glucuronidase (Gusb) were selected as
reference genes. Expression levels were analyzed using qBase software, an advanced quantification
tool based on the ∆∆Ct quantification method, and normalized against the geometric mean of the
three reference genes. All primers and probes are listed in Table 1, and constructed by Integrated DNA
Technologies (IDT).
4.4. Western Blotting
Retina and RPE samples from both genotypes were isolated and immediately transferred into ice
cold 100 µL lysis buffer (50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% Brij 35, and 1% Triton-X-100,
pH 7.5), supplemented with protease inhibitor (Roche Applied Science, Mannheim, Germany), one mini
tablet per 10 mL of lysis buffer). Samples were homogenized by sonication for 1 min and centrifuged
for 10 min at 18,000× g. Protein concentrations were determined according to the Bradford method
(Bio-Rad, Temse, Belgium). Proteins from retinal, RPE and vitreous samples were separated on 4%–12%
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NuPage® Bis-Tris gels (Invitrogen) and transferred using the TransBlot® TurboTM Transfer System
(Bio-Rad) onto PVDF or nitrocellulose membranes (Bio-Rad). The membranes were blocked for 2 h
in 5% commercial blocking powder (ECL™ Blocking agent, GE Healthcare, Diegem, Belgium) and
incubated overnight at 4 ◦C with antibodies to MMP-3 (1/200, Ab52915, Abcam, Cambridge, UK),
ICAM-1 (1/60, SC-1511, Santa Cruz, CA, USA) and ZO-1 (1/80, ab59720, Abcam). After incubation
with horseradish peroxidase (HRP)-labeled secondary antibodies, the membranes were incubated in
Supersignal® West Dura Extended Duration Substrate solution (Thermo Scientific). The ChemiDoc
MP Imager (Bio-Rad) was used to measure optical densities of the protein bands, which were
normalized against Lava purple total protein stain (Gelcompany, San Francisco, CA, USA). Western
blot experiments were performed on retinal/RPE/vitreous samples from at minimum 5 mice per
genotype and were repeated at least twice.
Table 1. Primer and probe sequences of the different genes used in RT-PCR.
Gene Forward Primer Reverse Primer Probe
Ywhaz cgtacctacaatgcctccatc catcctgctgtccattgctta tccttgattttgcctcagctccca
Rn18s1 cgtacctacaatgcctccatc agaattgcaacagctcgattg cagcccctgatgagaatgtaccagc
Gusb gacccaagataccgacatgag cagcttgctaatgtcagcct aatcccattcacccacacaactgc
Mmp3 gatgaacgatggacagaggatg tgtggaggacttgtagactgg tggttgctgctcatgaacttggc
Il6 tccttagccactccttctgt agccagagtccttcagaga cctaccccaatttccaatgctctcct
Il1b ctcttgttgatgtgctgctg gacctgttctttgaagttgacg ttccaaacctttgacctgggctgt
Tnfα tctttagatccatgccgttg agaccctcacactcagatca ccacgtcgtagcaaaccaccaagt
Nf-κBp65 ccctctgttttggttgctcta tgaacactgctttgactcact atgggccatctgttgacagtggt
Mcp1 aactacagcttctttgggaca catccacgtgttggctca actcacctgctgctactcattcacc
Cxcl1 gtgccatcagagcagtct ccaaaccgaagtcatagcca aggtgtccccaagtaacggagaaag
Icam1 ggtccttgcctacttgctg ctgtgctttgagaactgtgg ccgctaccatcaccgtgtattcgtt
Nos2 cacttctgctccaaatccaac gactgagctgttagagacactt tgaacaagacccaagcgtgaggag
Zo1 gcaactacagtatgaccatcc aatgaataatatcagcaccatgcc ctgtccctgtgagtccttcagctg
Rplp2 gtcatcgctcagggtgttg gactcctccttcttctcatctttc ctgtggctgtttctgctgccc
Hprt cgtgattagcgatgatgaacc catgacatctcgagcaagtct cctcatggactgattatggacaggactga
4.5. Immunohistochemistry (IHC)
Mice were deeply anesthetized (ip of 30 mg/kg sodium pentobarbital, Nembutal, Ceva,
Brussels, Belgium) and transcardially perfused with 4% phosphate buffered paraformaldehyde (PFA),
and sagittal paraffin- or cryosections (10 µm) of the eye were made. General eye morphology was
studied using hematoxylin and eosin (H&E) staining. To determine regional and cellular expression
of MMP-3, immunofluorescent stainings were performed. Briefly, upon antigen retrieval method
with heated citrate buffer (10 mM citric acid, 0.05% Tween 20, pH 6.0), endogenous peroxidases
were blocked by incubation in 0.3% H2O2 (in methanol) for 20 min, and subsequently incubated
with 20% pre-immune serum before overnight incubation with the primary antibody MMP-3 (1/200,
Ab52915, Abcam). Next, Alexa Fluor-conjugated secondary antibodies (Invitrogen) or the TSATM
FITC kit (PerkinElmer, Waltham, MA, USA) were applied as previously published [96,97] and stained
sections were examined and photographed using an Olympus FV1000 confocal microscope (Olympus,
Berchem, Belgium).
4.6. Multiplex Cytokine Assay
The BD cytokine bead array (CBA) kit (BD Biosciences, San Jose, CA, USA) was used to
quantitatively measure chemokines CXCL1 (or KC) and MCP-1, in the retina and RPE of WT and
MMP-3−/− mice subjected to EIU. Samples were prepared as described above for Western blot,
and 25 µL of mouse cytokine standards and samples were used to enable fluorescence detection of the
antibody-coated beads, according to the manufacturer’s instructions. Flow cytometry was performed
using the BD FACS canto HTS (BD Biosciences). CBA results were analyzed using FCAP ArrayTM
software (BD Biosciences).
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4.7. Retinal Leukocyte Adhesion Quantification
Mice were deeply anaesthetized (ip injection of 30 mg/kg sodium pentobarbital, Nembutal,
Ceva) at 24 hpi and were transcardially perfused with NaCl 0.9% + heparin (71 mg/L) during 5 min
(2–3 mL/min) to remove erythrocytes and non-adherent leukocytes. Next, the animals were perfused
with 25 mL of FITC-Concanavalin A lectin (FITC-ConA; 40 µg/mL in PBS 1X, pH 7.5) at a flow
rate of 10 mL/min, followed by removal of unbound FITC-ConA with NaCl-heparin during 5 min
(2–3 mL/min). After cervical dislocation, the eyes were isolated, incubated overnight in 1% PFA
and flatmounted. Each retina was visualized under a Leica DM IL LED microscope (Leica, Wetzlar,
Germany) and the total number of FITC-ConA stained adherent leukocytes was counted by a blinded
investigator, in all arterioles and venules. Representative pictures were taken using an Olympus
FV1000 confocal microscope.
4.8. Optical Coherence Tomography
To assess thickness of the retinal layers and retinal morphology in general, and to evaluate
inflammatory leukocyte infiltration into the vitreous cavity at 24 hpi in vivo, a spectral domain optical
coherence tomography (SD-OCT) system (Envisu R2210, Bioptigen, Morrisville, NC, USA) was used.
After anesthetizing the mouse via ip injection of 75 mg/kg body weight ketamine (Anesketin, Eurovet,
Bladel, The Netherlands) and 1 mg/kg medetomidine (Domitor, Pfizer, NY, USA), topical application
of 0.5% tropicamide (0.5% Tropicol, Thea Pharma, Wetteren, Belgium) was used to dilute the pupils.
Next, SD-OCT was accomplished via 100 serial B-scan lines with each line consisting of 1000 A-scans,
in a 1.4 mm × 1.4 mm field. Afterwards, ip injection of atipamezol (1 mg/kg, Antisedan, Pfizer) was
applied to reverse the anesthesia, followed by antibiotic ointment to the eye (tobramycin 3 mg/g,
Tobrex, Alcon, Puurs, Belgium) To evaluate retinal morphology, total retinal thickness and thickness
of the ganglion cell complex (GCC), which comprises the nerve fiber layer (NFL), ganglion cell layer
(GCL) and the inner plexiform layer (IPL), of WT and MMP-3−/− mice were analyzed using InVivoVue
Diver 2.2 software (Bioptigen). Cellular infiltrates were defined as hyperreflective dots in the vitreous
cavity that were larger and of greater density than background noise [98]. Per eye, these infiltrating
leukocytes were measured manually over a distance of 500 µm around the optic nerve head on 5 B-scan
images: 1 B-scan image centered at the optic nerve head, and 4 images at 50 µm intervals from the
optic nerve head (2 anterior, 2 posterior) (see also Figure 4D). Values of these 5 images were summed
up to yield a representative number of infiltrating leukocytes for each retina.
4.9. Optokinetic Tracking Response
The optokinetic tracking response was performed in photopic conditions in a virtual-reality
chamber (OptoMotry, Cerebral Mechanics, Medicine Hat, AB, Canada), as previously
described [99–101]. Briefly, the mouse was situated on a platform in the middle of a virtual cylinder,
that consist of a vertical sine wave grating projecting on four computer screens into a closed box.
Real-time video feedback is provided via a video camera placed above the mouse. Visual acuity of each
eye was determined using a staircase procedure, composed of randomly different spatial frequencies
(100% contrast, 12◦ per second speed). A blinded experimenter determined the maximum spatial
frequency at which optokinetic tracking was seen.
4.10. Statistical Analysis
All values are represented as mean ± SEM. Statistical analyses were performed with GraphPad
Prism 6 (GraphPad Software, San Diego, CA, USA) using student’s t-test, one or two way-ANOVA,
with Tukey’s multiple comparisons or a Bonferroni test as post-hoc tests. For all statistical tests,
a p-value of 0.05 was considered statistically significant.
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CNS central nervous system
LPS lipopolysaccharide
MMP-3 matrix metalloproteinase 3
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BCSFB blood–cerebrospinal fluid barrier
BSCB blood–spinal cord barrier
ICAM-1 intercellular adhesion molecule 1
IL/Il interleukin
NOS2 nitric oxide synthase 2
MCP-1 monocyte chemoattractant protein 1
CXCL1 (C-X-C motif) ligand 1
TNF-α tumor necrosis factor α
NF-κB p65 nuclear factor kappa B p65 subunit
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References
1. Caspi, R.R. A look at autoimmunity and inflammation in the eye. J. Clin. Investig. 2010, 120, 3073–3083.
[CrossRef] [PubMed]
2. Crane, I.J.; Liversidge, J. Mechanisms of leukocyte migration across the blood-retina barrier. Semin. Immunopathol.
2008, 30, 165–177. [CrossRef] [PubMed]
3. Yadav, U.C.; Ramana, K.V. Endotoxin-induced uveitis in rodents. Methods Mol. Biol. 2013, 1031, 155–162.
[PubMed]
4. Kanda, A.; Noda, K.; Oike, Y.; Ishida, S. Angiopoietin-like protein 2 mediates endotoxin-induced acute
inflammation in the eye. Lab. Investig. J. Tech. Methods Pathol. 2012, 92, 1553–1563. [CrossRef] [PubMed]
5. Suzuki, M.; Noda, K.; Kubota, S.; Hirasawa, M.; Ozawa, Y.; Tsubota, K.; Mizuki, N.; Ishida, S.
Eicosapentaenoic acid suppresses ocular inflammation in endotoxin-induced uveitis. Mol. Vis. 2010,
16, 1382–1388. [PubMed]
6. Tuaillon, N.; Shen, D.F.; Berger, R.B.; Lu, B.; Rollins, B.J.; Chan, C.C. Mcp-1 expression in endotoxin-induced
uveitis. Investig. Ophthalmol. Vis. Sci. 2002, 43, 1493–1498.
7. Hoekzema, R.; Verhagen, C.; van Haren, M.; Kijlstra, A. Endotoxin-induced uveitis in the rat. The significance
of intraocular interleukin-6. Ophthalmol. Vis. Sci. 1992, 33, 532–539.
8. Koizumi, K.; Poulaki, V.; Doehmen, S.; Welsandt, G.; Radetzky, S.; Lappas, A.; Kociok, N.; Kirchhof, B.;
Joussen, A.M. Contribution of TNF-α to leukocyte adhesion, vascular leakage, and apoptotic cell death in
endotoxin-induced uveitis in vivo. Ophthalmol. Vis. Sci. 2003, 44, 2184–2191. [CrossRef]
9. Satofuka, S.; Ichihara, A.; Nagai, N.; Yamashiro, K.; Koto, T.; Shinoda, H.; Noda, K.; Ozawa, Y.; Inoue, M.;
Tsubota, K.; et al. Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting
nonproteolytic activation of prorenin. Ophthalmol. Vis. Sci. 2006, 47, 2686–2692. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 1825 19 of 23
10. Zhang, W.; Baban, B.; Rojas, M.; Tofigh, S.; Virmani, S.K.; Patel, C.; Behzadian, M.A.; Romero, M.J.;
Caldwell, R.W.; Caldwell, R.B. Arginase activity mediates retinal inflammation in endotoxin-induced uveitis.
Am. J. Pathol. 2009, 175, 891–902. [CrossRef] [PubMed]
11. Gurney, K.J.; Estrada, E.Y.; Rosenberg, G.A. Blood-brain barrier disruption by stromelysin-1 facilitates
neutrophil infiltration in neuroinflammation. Neurobiol. Dis. 2006, 23, 87–96. [CrossRef] [PubMed]
12. Yang, Y.; Rosenberg, G.A. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease.
Stroke J. Cereb. Circ. 2011, 42, 3323–3328. [CrossRef] [PubMed]
13. Vandenbroucke, R.E.; Dejonckheere, E.; van Lint, P.; Demeestere, D.; van Wonterghem, E.; Vanlaere, I.;
Puimege, L.; van Hauwermeiren, F.; de Rycke, R.; Mc Guire, C.; et al. Matrix metalloprotease 8-dependent
extracellular matrix cleavage at the blood-CSF barrier contributes to lethality during systemic inflammatory
diseases. J. Neurosci. 2012, 32, 9805–9816. [CrossRef] [PubMed]
14. Brkic, M.; Balusu, S.; van Wonterghem, E.; Gorle, N.; Benilova, I.; Kremer, A.; van Hove, I.; Moons, L.;
de Strooper, B.; Kanazir, S.; et al. Amyloid β oligomers disrupt blood-CSF barrier integrity by activating
matrix metalloproteinases. J. Neurosci. 2015, 35, 12766–12778. [CrossRef] [PubMed]
15. Wiggins-Dohlvik, K.; Merriman, M.; Shaji, C.A.; Alluri, H.; Grimsley, M.; Davis, M.L.; Smith, R.W.;
Tharakan, B. Tumor necrosis factor-α disruption of brain endothelial cell barrier is mediated through
matrix metalloproteinase-9. Am. J. Surg. 2014, 208, 954–960. [CrossRef] [PubMed]
16. Lee, J.Y.; Choi, H.Y.; Ahn, H.J.; Ju, B.G.; Yune, T.Y. Matrix metalloproteinase-3 promotes early blood-spinal
cord barrier disruption and hemorrhage and impairs long-term neurological recovery after spinal cord injury.
Am. J. Pathol. 2014, 184, 2985–3000. [CrossRef] [PubMed]
17. Noble, L.J.; Donovan, F.; Igarashi, T.; Goussev, S.; Werb, Z. Matrix metalloproteinases limit functional
recovery after spinal cord injury by modulation of early vascular events. J. Neurosci. 2002, 22, 7526–7535.
[PubMed]
18. Lakhan, S.E.; Kirchgessner, A.; Tepper, D.; Leonard, A. Matrix metalloproteinases and blood-brain barrier
disruption in acute ischemic stroke. Front. Neurol. 2013, 4, 32. [CrossRef] [PubMed]
19. Yang, Y.; Estrada, E.Y.; Thompson, J.F.; Liu, W.; Rosenberg, G.A. Matrix metalloproteinase-mediated
disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase
inhibitor in focal ischemia in rat. J. Cereb. Blood Flow Metab. 2007, 27, 697–709. [CrossRef] [PubMed]
20. Neuwelt, E.; Abbott, N.J.; Abrey, L.; Banks, W.A.; Blakley, B.; Davis, T.; Engelhardt, B.; Grammas, P.;
Nedergaard, M.; Nutt, J.; et al. Strategies to advance translational research into brain barriers. Lancet Neurol.
2008, 7, 84–96. [CrossRef]
21. Mun-Bryce, S.; Lukes, A.; Wallace, J.; Lukes-Marx, M.; Rosenberg, G.A. Stromelysin-1 and gelatinase a are
upregulated before TNF-α in LPS-stimulated neuroinflammation. Brain Res. 2002, 933, 42–49. [CrossRef]
22. Chung, Y.C.; Kim, Y.S.; Bok, E.; Yune, T.Y.; Maeng, S.; Jin, B.K. MMP-3 contributes to nigrostriatal
dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of parkinson’s
disease. Mediat. Inflamm. 2013, 2013, 370526. [CrossRef] [PubMed]
23. Ljubisavljevic, S.; Stojanovic, I.; Basic, J.; Vojinovic, S.; Stojanov, D.; Djordjevic, G.; Pavlovic, D. The role of
matrix metalloproteinase 3 and 9 in the pathogenesis of acute neuroinflammation. Implications for disease
modifying therapy. J. Mol. Neurosci. 2015, 56, 840–847. [CrossRef] [PubMed]
24. Jalal, F.Y.; Yang, Y.; Thompson, J.; Lopez, A.C.; Rosenberg, G.A. Myelin loss associated with
neuroinflammation in hypertensive rats. Stroke 2012, 43, 1115–1122. [CrossRef] [PubMed]
25. Brkic, M.; Balusu, S.; Libert, C.; Vandenbroucke, R.E. Friends or foes: Matrix metalloproteinases and their
multifaceted roles in neurodegenerative diseases. Mediat. Inflamm. 2015, 2015, 620581. [CrossRef] [PubMed]
26. Grossetete, M.; Phelps, J.; Arko, L.; Yonas, H.; Rosenberg, G.A. Elevation of matrix metalloproteinases 3
and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury. Neurosurgery 2009, 65,
702–708. [CrossRef] [PubMed]
27. Kyriakis, J.M. Activation of the AP-1 transcription factor by inflammatory cytokines of the TNF family.
Gene Expr. 1999, 7, 217–231. [PubMed]
28. Overall, C.M.; Lopez-Otin, C. Strategies for MMP inhibition in cancer: Innovations for the post-trial era.
Nat. Rev. Cancer 2002, 2, 657–672. [CrossRef] [PubMed]
29. Rosenberg, G.A. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases.
Lancet Neurol. 2009, 8, 205–216. [CrossRef]
Int. J. Mol. Sci. 2016, 17, 1825 20 of 23
30. Candelario-Jalil, E.; Taheri, S.; Yang, Y.; Sood, R.; Grossetete, M.; Estrada, E.Y.; Fiebich, B.L.; Rosenberg, G.A.
Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor
necrosis factor-α in the rat. J. Pharmacol. Exp. Ther. 2007, 323, 488–498. [CrossRef] [PubMed]
31. Kim, E.M.; Hwang, O. Role of matrix metalloproteinase-3 in neurodegeneration. J. Neurochem. 2011, 116,
22–32. [CrossRef] [PubMed]
32. Woo, M.S.; Park, J.S.; Choi, I.Y.; Kim, W.K.; Kim, H.S. Inhibition of MMP-3 or -9 suppresses
lipopolysaccharide-induced expression of proinflammatory cytokines and inos in microglia. J. Neurochem.
2008, 106, 770–780. [CrossRef] [PubMed]
33. Frankowski, J.C.; DeMars, K.M.; Ahmad, A.S.; Hawkins, K.E.; Yang, C.; Leclerc, J.L.; Dore, S.;
Candelario-Jalil, E. Detrimental role of the EP1 prostanoid receptor in blood-brain barrier damage following
experimental ischemic stroke. Sci. Rep. 2015, 5, 17956. [CrossRef] [PubMed]
34. Eichler, W.; Friedrichs, U.; Thies, A.; Tratz, C.; Wiedemann, P. Modulation of matrix metalloproteinase and
TIMP-1 expression by cytokines in human RPE cells. Ophthalmol. Vis. Sci. 2002, 43, 2767–2773.
35. Li, H.; Yoneda, M.; Takeyama, M.; Sugita, I.; Tsunekawa, H.; Yamada, H.; Watanabe, D.; Mukai, T.;
Yamamura, M.; Iwaki, M.; et al. Effect of infliximab on tumor necrosis factor-α-induced alterations in
retinal microvascular endothelial cells and retinal pigment epithelial cells. J. Ocul. Pharmacol. Ther. 2010, 26,
549–556. [CrossRef] [PubMed]
36. Leu, S.T.; Batni, S.; Radeke, M.J.; Johnson, L.V.; Anderson, D.H.; Clegg, D.O. Drusen are cold spots for
proteolysis: Expression of matrix metalloproteinases and their tissue inhibitor proteins in age-related
macular degeneration. Exp. Eye Res. 2002, 74, 141–154. [CrossRef] [PubMed]
37. Nemzek, J.A.; Hugunin, K.M.; Opp, M.R. Modeling sepsis in the laboratory: Merging sound science with
animal well-being. Comp. Med. 2008, 58, 120–128. [PubMed]
38. Choi, D.H.; Kim, J.H.; Seo, J.H.; Lee, J.; Choi, W.S.; Kim, Y.S. Matrix metalloproteinase-3 causes dopaminergic
neuronal death through Nox1-regenerated oxidative stress. PLoS ONE 2014, 9, e115954. [CrossRef] [PubMed]
39. Christianson, C.A.; Fitzsimmons, B.L.; Shim, J.H.; Agrawal, A.; Cohen, S.M.; Hua, X.Y.; Yaksh, T.L. Spinal
matrix metalloproteinase 3 mediates inflammatory hyperalgesia via a tumor necrosis factor-dependent
mechanism. Neuroscience 2012, 200, 199–210. [CrossRef] [PubMed]
40. Pauly, T.; Ratliff, M.; Pietrowski, E.; Neugebauer, R.; Schlicksupp, A.; Kirsch, J.; Kuhse, J. Activity-dependent
shedding of the nmda receptor glycine binding site by matrix metalloproteinase 3: A putative mechanism of
postsynaptic plasticity. PLoS ONE 2008, 3, e2681. [CrossRef] [PubMed]
41. Chu, C.J.; Gardner, P.J.; Copland, D.A.; Liyanage, S.E.; Gonzalez-Cordero, A.; Kleine Holthaus, S.M.;
Luhmann, U.F.; Smith, A.J.; Ali, R.R.; Dick, A.D. Multimodal analysis of ocular inflammation using the
endotoxin-induced uveitis mouse model. Dis. Models Mech. 2016, 9, 473–481. [CrossRef] [PubMed]
42. Gadjanski, I.; Williams, S.K.; Hein, K.; Sattler, M.B.; Bahr, M.; Diem, R. Correlation of optical coherence
tomography with clinical and histopathological findings in experimental autoimmune uveoretinitis.
Exp. Eye Res. 2011, 93, 82–90. [CrossRef] [PubMed]
43. Chu, C.J.; Herrmann, P.; Carvalho, L.S.; Liyanage, S.E.; Bainbridge, J.W.; Ali, R.R.; Dick, A.D.; Luhmann, U.F.
Assessment and in vivo scoring of murine experimental autoimmune uveoretinitis using optical coherence
tomography. PLoS ONE 2013, 8, e63002. [CrossRef] [PubMed]
44. Fuentes, M.E.; Durham, S.K.; Swerdel, M.R.; Lewin, A.C.; Barton, D.S.; Megill, J.R.; Bravo, R.; Lira, S.A.
Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of
monocyte chemoattractant protein-1. J. Immunol. 1995, 155, 5769–5776. [PubMed]
45. Becker, M.D.; Garman, K.; Whitcup, S.M.; Planck, S.R.; Rosenbaum, J.T. Inhibition of leukocyte sticking
and infiltration, but not rolling, by antibodies to ICAM-1 and LFA-1 in murine endotoxin-induced uveitis.
Ophthalmol. Vis. Sci. 2001, 42, 2563–2566.
46. Choi, D.H.; Kim, E.M.; Son, H.J.; Joh, T.H.; Kim, Y.S.; Kim, D.; Flint Beal, M.; Hwang, O. A novel intracellular
role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. J. Neurochem. 2008, 106, 405–415.
[CrossRef] [PubMed]
47. Gasche, Y.; Copin, J.C.; Sugawara, T.; Fujimura, M.; Chan, P.H. Matrix metalloproteinase inhibition prevents
oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J. Cereb.
Blood Flow Metab. 2001, 21, 1393–1400. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 1825 21 of 23
48. Zeni, P.; Doepker, E.; Schulze-Topphoff, U.; Huewel, S.; Tenenbaum, T.; Galla, H.J. MMPs contribute to
TNF-α-induced alteration of the blood-cerebrospinal fluid barrier in vitro. Am. J. Physiol. Cell Physiol. 2007,
293, C855–C864. [CrossRef] [PubMed]
49. Sudharshan, S.; Ganesh, S.K.; Biswas, J. Current approach in the diagnosis and management of posterior
uveitis. Indian J. Ophthalmol. 2010, 58, 29–43. [PubMed]
50. Kubota, S.; Kurihara, T.; Mochimaru, H.; Satofuka, S.; Noda, K.; Ozawa, Y.; Oike, Y.; Ishida, S.; Tsubota, K.
Prevention of ocular inflammation in endotoxin-induced uveitis with resveratrol by inhibiting oxidative
damage and nuclear factor-kappab activation. Ophthalmol. Vis. Sci. 2009, 50, 3512–3519. [CrossRef] [PubMed]
51. Page-McCaw, A.; Ewald, A.J.; Werb, Z. Matrix metalloproteinases and the regulation of tissue remodelling.
Nat. Rev. Mol. Cell Biol. 2007, 8, 221–233. [CrossRef] [PubMed]
52. De Groef, L.; Andries, L.; Lemmens, K.; van Hove, I.; Moons, L. Matrix metalloproteinases in the mouse
retina: A comparative study of expression patterns and mmp antibodies. BMC Ophthalmol. 2015, 15, 187.
[CrossRef] [PubMed]
53. Sternlicht, M.D.; Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol.
2001, 17, 463–516. [CrossRef] [PubMed]
54. Rajagopalan, S.; Meng, X.P.; Ramasamy, S.; Harrison, D.G.; Galis, Z.S. Reactive oxygen species produced
by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro.
Implications for atherosclerotic plaque stability. J. Clin. Investig. 1996, 98, 2572–2579. [CrossRef] [PubMed]
55. Hsu, H.Y.; Wen, M.H. Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the
regulation of interleukin-1 gene expression. J. Biol. Chem. 2002, 277, 22131–22139. [CrossRef] [PubMed]
56. Sasaki, M.; Ozawa, Y.; Kurihara, T.; Noda, K.; Imamura, Y.; Kobayashi, S.; Ishida, S.; Tsubota, K.
Neuroprotective effect of an antioxidant, lutein, during retinal inflammation. Ophthalmol. Vis. Sci. 2009, 50,
1433–1439. [CrossRef] [PubMed]
57. Kowluru, R.A.; Chan, P.S. Oxidative stress and diabetic retinopathy. Exp. Diabetes Res. 2007, 2007, 43603.
[CrossRef] [PubMed]
58. Neria, F.; del Carmen Serrano-Perez, M.; Velasco, P.; Urso, K.; Tranque, P.; Cano, E. Nfatc3 promotes
Ca2+ -dependent Mmp3 expression in astroglial cells. Glia 2013, 61, 1052–1066. [CrossRef] [PubMed]
59. Bouwmeester, T.; Bauch, A.; Ruffner, H.; Angrand, P.O.; Bergamini, G.; Croughton, K.; Cruciat, C.;
Eberhard, D.; Gagneur, J.; Ghidelli, S.; et al. A physical and functional map of the human TNF-α/NF-κB
signal transduction pathway. Nat. Cell Biol. 2004, 6, 97–105. [CrossRef] [PubMed]
60. Skipor, J.; Szczepkowska, A.; Kowalewska, M.; Herman, A.P.; Lisiewski, P. Profile of toll-like receptor mRNA
expression in the choroid plexus in adult ewes. Acta Vet. Hung. 2015, 63, 69–78. [CrossRef] [PubMed]
61. Lu, Y.C.; Yeh, W.C.; Ohashi, P.S. LPS/TLR4 signal transduction pathway. Cytokine 2008, 42, 145–151.
[CrossRef] [PubMed]
62. Jiang, Q.; Akashi, S.; Miyake, K.; Petty, H.R. Lipopolysaccharide induces physical proximity between CD14
and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-κB. J. Immunol. 2000, 165, 3541–3544.
[CrossRef] [PubMed]
63. Mallard, C. Innate immune regulation by toll-like receptors in the brain. ISRN Neurol. 2012, 2012, 701950.
[CrossRef] [PubMed]
64. Elner, S.G.; Petty, H.R.; Elner, V.M.; Yoshida, A.; Bian, Z.M.; Yang, D.; Kindezelskii, A.L. TLR4 mediates
human retinal pigment epithelial endotoxin binding and cytokine expression. Trans. Am. Ophthalmol. Soc.
2005, 103, 126–135. [CrossRef] [PubMed]
65. Alge-Priglinger, C.S.; Kreutzer, T.; Obholzer, K.; Wolf, A.; Mempel, M.; Kernt, M.; Kampik, A.; Priglinger, S.G.
Oxidative stress-mediated induction of MMP-1 and MMP-3 in human RPE cells. Ophthalmol. Vis. Sci. 2009,
50, 5495–5503. [CrossRef] [PubMed]
66. Chen, H.; Liu, B.; Lukas, T.J.; Neufeld, A.H. The aged retinal pigment epithelium/choroid: A potential
substratum for the pathogenesis of age-related macular degeneration. PLoS ONE 2008, 3, e2339. [CrossRef]
[PubMed]
67. Tenenbaum, T.; Matalon, D.; Adam, R.; Seibt, A.; Wewer, C.; Schwerk, C.; Galla, H.J.; Schroten, H.
Dexamethasone prevents alteration of tight junction-associated proteins and barrier function in porcine
choroid plexus epithelial cells after infection with streptococcus suis in vitro. Brain Res. 2008, 1229, 1–17.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 1825 22 of 23
68. Al-Saffar, H.; Lewis, K.; Liu, E.; Schober, A.; Corrigan, J.J.; Shibata, K.; Steiner, A.A.
Lipopolysaccharide-induced hypothermia and hypotension are associated with inflammatory signaling that
is triggered outside the brain. Brain Behav. Immun. 2013, 28, 188–195. [CrossRef] [PubMed]
69. Leon, L.R. Hypothermia in systemic inflammation: Role of cytokines. Front. Biosci. 2004, 9, 1877–1888.
[CrossRef] [PubMed]
70. Kaplanski, J.; Nassar, A.; Sharon-Granit, Y.; Jabareen, A.; Kobal, S.L.; Azab, A.N. Lithium attenuates
lipopolysaccharide-induced hypothermia in rats. Eur. Rev. Med. Pharmacol. Sci. 2014, 18, 1829–1837.
[PubMed]
71. Vanlaere, I.; Libert, C. Matrix metalloproteinases as drug targets in infections caused by gram-negative
bacteria and in septic shock. Clin. Microbiol. Rev. 2009, 22, 224–239. [CrossRef] [PubMed]
72. Lipowsky, H.H.; Sah, R.; Lescanic, A. Relative roles of doxycycline and cation chelation in endothelial glycan
shedding and adhesion of leukocytes. Am. J. Physiol. Heart Circ. Physiol. 2011, 300, H415–H422. [CrossRef]
[PubMed]
73. Vandenbroucke, R.E.; Vanlaere, I.; van Hauwermeiren, F.; van Wonterghem, E.; Wilson, C.; Libert, C.
Pro-inflammatory effects of matrix metalloproteinase 7 in acute inflammation. Mucosal Immunol. 2014, 7,
579–588. [CrossRef] [PubMed]
74. Aerts, J.; Vandenbroucke, R.E.; Dera, R.; Balusu, S.; van Wonterghem, E.; Moons, L.; Libert, C.;
Dehaen, W.; Arckens, L. Synthesis and validation of a hydroxypyrone-based, potent, and specific matrix
metalloproteinase-12 inhibitor with anti-inflammatory activity in vitro and in vivo. Mediat. Inflamm. 2015,
2015, 510679. [CrossRef] [PubMed]
75. Vandenbroucke, R.E.; Dejonckheere, E.; van Hauwermeiren, F.; Lodens, S.; de Rycke, R.; van Wonterghem, E.;
Staes, A.; Gevaert, K.; Lopez-Otin, C.; Libert, C. Matrix metalloproteinase 13 modulates intestinal epithelial
barrier integrity in inflammatory diseases by activating TNF. EMBO Mol. Med. 2013, 5, 1000–1016. [CrossRef]
[PubMed]
76. Shen, D.F.; Buggage, R.R.; Eng, H.C.; Chan, C.C. Cytokine gene expression in different strains of mice with
endotoxin-induced uveitis (EIU). Ocul. Immunol. Inflamm. 2000, 8, 221–225. [CrossRef] [PubMed]
77. Planck, S.R.; Huang, X.N.; Robertson, J.E.; Rosenbaum, J.T. Cytokine mRNA levels in rat ocular tissues after
systemic endotoxin treatment. Ophthalmol. Vis. Sci. 1994, 35, 924–930.
78. Hoekzema, R.; Murray, P.I.; van Haren, M.A.; Helle, M.; Kijlstra, A. Analysis of interleukin-6 in
endotoxin-induced uveitis. Ophthalmol. Vis. Sci. 1991, 32, 88–95.
79. Leung, K.W.; Barnstable, C.J.; Tombran-Tink, J. Bacterial endotoxin activates retinal pigment epithelial cells
and induces their degeneration through IL-6 and IL-8 autocrine signaling. Mol. Immunol. 2009, 46, 1374–1386.
[CrossRef] [PubMed]
80. De Vos, A.F.; Klaren, V.N.; Kijlstra, A. Expression of multiple cytokines and IL-1RA in the uvea and retina
during endotoxin-induced uveitis in the rat. Ophthalmol. Vis. Sci. 1994, 35, 3873–3883.
81. Ley, K.; Laudanna, C.; Cybulsky, M.I.; Nourshargh, S. Getting to the site of inflammation: The leukocyte
adhesion cascade updated. Nat. Rev. Immunol. 2007, 7, 678–689. [CrossRef] [PubMed]
82. Li, X.; Gu, X.; Boyce, T.M.; Zheng, M.; Reagan, A.M.; Qi, H.; Mandal, N.; Cohen, A.W.; Callegan, M.C.;
Carr, D.J.; et al. Caveolin-1 increases proinflammatory chemoattractants and blood-retinal barrier breakdown
but decreases leukocyte recruitment in inflammation. Ophthalmol. Vis. Sci. 2014, 55, 6224–6234. [CrossRef]
[PubMed]
83. Benhar, I.; Reemst, K.; Kalchenko, V.; Schwartz, M. The retinal pigment epithelium as a gateway for monocyte
trafficking into the eye. EMBO J. 2016, 35, 1219–1235. [CrossRef] [PubMed]
84. Goureau, O.; Bellot, J.; Thillaye, B.; Courtois, Y.; de Kozak, Y. Increased nitric oxide production in
endotoxin-induced uveitis. Reduction of uveitis by an inhibitor of nitric oxide synthase. J. Immunol.
1995, 154, 6518–6523. [PubMed]
85. Shi, F.; Duan, S.; Cui, J.; Yan, X.; Li, H.; Wang, Y.; Chen, F.; Zhang, L.; Liu, J.; Xie, X. Induction of matrix
metalloproteinase-3 (MMP-3) expression in the microglia by lipopolysaccharide (LPS) via upregulation of
glycoprotein nonmetastatic melanoma B (GPNMB) expression. J. Mol. Neurosci. 2014, 54, 234–242. [CrossRef]
[PubMed]
86. Sinfield, J.K.; Das, A.; O’Regan, D.J.; Ball, S.G.; Porter, K.E.; Turner, N.A. P38 MAPK alpha mediates
cytokine-induced IL-6 and MMP-3 expression in human cardiac fibroblasts. Biochem. Biophys. Res. Commun.
2013, 430, 419–424. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 1825 23 of 23
87. Neuder, L.E.; Keener, J.M.; Eckert, R.E.; Trujillo, J.C.; Jones, S.L. Role of p38 MAPK in LPS induced
pro-inflammatory cytokine and chemokine gene expression in equine leukocytes. Vet. Immunol. Immunopathol.
2009, 129, 192–199. [CrossRef] [PubMed]
88. Guha, M.; O’Connell, M.A.; Pawlinski, R.; Hollis, A.; McGovern, P.; Yan, S.F.; Stern, D.; Mackman, N.
Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor
and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and EGR-1 expression. Blood
2001, 98, 1429–1439. [CrossRef] [PubMed]
89. Steenport, M.; Khan, K.M.; Du, B.; Barnhard, S.E.; Dannenberg, A.J.; Falcone, D.J. Matrix metalloproteinase
(MMP)-1 and MMP-3 induce macrophage MMP-9: Evidence for the role of TNF-α and cyclooxygenase-2.
J. Immunol. 2009, 183, 8119–8127. [CrossRef] [PubMed]
90. Gearing, A.J.; Beckett, P.; Christodoulou, M.; Churchill, M.; Clements, J.M.; Crimmin, M.; Davidson, A.H.;
Drummond, A.H.; Galloway, W.A.; Gilbert, R.; et al. Matrix metalloproteinases and processing of pro-TNF-α.
J. Leukoc. Biol. 1995, 57, 774–777. [PubMed]
91. Konari, K.; Sawada, N.; Zhong, Y.; Isomura, H.; Nakagawa, T.; Mori, M. Development of the blood-retinal
barrier in vitro: Formation of tight junctions as revealed by occludin and ZO-1 correlates with the barrier
function of chick retinal pigment epithelial cells. Exp. Eye Res. 1995, 61, 99–108. [CrossRef]
92. Russ, P.K.; Davidson, M.K.; Hoffman, L.H.; Haselton, F.R. Partial characterization of the human retinal
endothelial cell tight and adherens junction complexes. Ophthalmol. Vis. Sci. 1998, 39, 2479–2485.
93. Poulaki, V.; Iliaki, E.; Mitsiades, N.; Mitsiades, C.S.; Paulus, Y.N.; Bula, D.V.; Gragoudas, E.S.; Miller, J.W.
Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis. FASEB J. 2007, 21, 2113–2123.
[CrossRef] [PubMed]
94. Zech, J.C.; Pouvreau, I.; Cotinet, A.; Goureau, O.; Le Varlet, B.; de Kozak, Y. Effect of cytokines and nitric
oxide on tight junctions in cultured rat retinal pigment epithelium. Ophthalmol. Vis. Sci. 1998, 39, 1600–1608.
95. Vanden Berghe, T.; Hulpiau, P.; Martens, L.; Vandenbroucke, R.E.; van Wonterghem, E.; Perry, S.W.;
Bruggeman, I.; Divert, T.; Choi, S.M.; Vuylsteke, M.; et al. Passenger mutations confound interpretation of all
genetically modified congenic mice. Immunity 2015, 43, 200–209. [CrossRef] [PubMed]
96. Verslegers, M.; van Hove, I.; Dekeyster, E.; Gantois, I.; Hu, T.T.; D’Hooge, R.; Arckens, L.; Moons, L. MMP-2
mediates purkinje cell morphogenesis and spine development in the mouse cerebellum. Brain Struct. Funct.
2015, 220, 1601–1617. [CrossRef] [PubMed]
97. Van Hove, I.; Verslegers, M.; Buyens, T.; Delorme, N.; Lemmens, K.; Stroobants, S.; Gantois, I.; D’Hooge, R.;
Moons, L. An aberrant cerebellar development in mice lacking matrix metalloproteinase-3. Mol. Neurobiol.
2012, 45, 17–29. [CrossRef] [PubMed]
98. Saito, M.; Barbazetto, I.A.; Spaide, R.F. Intravitreal cellular infiltrate imaged as punctate spots by
spectral-domain optical coherence tomography in eyes with posterior segment inflammatory disease. Retina
2013, 33, 559–565. [CrossRef] [PubMed]
99. Prusky, G.T.; Alam, N.M.; Beekman, S.; Douglas, R.M. Rapid quantification of adult and developing mouse
spatial vision using a virtual optomotor system. Investig. Ophthalmol. Vis. Sci. 2004, 45, 4611–4616. [CrossRef]
[PubMed]
100. Douglas, R.M.; Alam, N.M.; Silver, B.D.; McGill, T.J.; Tschetter, W.W.; Prusky, G.T. Independent visual
threshold measurements in the two eyes of freely moving rats and mice using a virtual-reality optokinetic
system. Vis. Neurosci. 2005, 22, 677–684. [CrossRef] [PubMed]
101. De Groef, L.; Dekeyster, E.; Geeraerts, E.; Lefevere, E.; Stalmans, I.; Salinas-Navarro, M.; Moons, L.
Differential visual system organization and susceptibility to experimental models of optic neuropathies in
three commonly used mouse strains. Exp. Eye Res. 2016, 145, 235–247. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
